A Preference Study Comparing Kristalose® and Liquid Lactulose
NCT ID: NCT00712543
Last Updated: 2011-09-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2009-06-30
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Kristalose®, as prescribed, for 7 days.
lactulose (Kristalose®)
Crystals to be dissolved in water and taken as prescribed.
2
Liquid lactulose, as prescribed, for 7 days.
liquid lactulose
Liquid to be taken as prescribed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lactulose (Kristalose®)
Crystals to be dissolved in water and taken as prescribed.
liquid lactulose
Liquid to be taken as prescribed.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients less than 18 years of age.
* Patients currently on lactulose therapy.
* Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board \[IRB\]) and agree to abide by the study restrictions.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cumberland Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arya Gastroenterology Associates
Brooklyn, New York, United States
Wake Research Associates
Raleigh, North Carolina, United States
Rapid Medical Research
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KR-001
Identifier Type: -
Identifier Source: org_study_id